ТАКРОЛИМУС ПРИ ТРАНСПЛАНТАЦИИ ПОЧКИ. СООБЩЕНИЕ I

такролимус, почечная недостаточность, трансплантация почки

1. Kino T, Hatanaka H, Hashimoto H et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 1987;40:1249–55. Kino T, Hatanaka H, Miyata S et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 1987; 40:1256–1265

2. Goto T, Kino T, Hatanaka H et al. FK506: historical perspectives. Transplant Proc 1991; 23: 2713–2717

3. Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 1987; 139: 1797–1803

4. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746–794

5. Inamura N, Nakahara K, Kino T et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation 1988;45:206–209

6. Ochiai T, Nagata M, Nakajima K et al. Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation 1987; 44: 729–733

7. Ochiai T, Gunji Y, Sakamoto K et al. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. Transplantation 1989; 48: 189–193

8. Ochiai T, Sakamoto K, Gunji Y et al. Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. Transplantation 1989; 48: 193–197

9. Todo S, Ueda Y, Demetris JA et al. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery 1988; 104: 239–249

10. Todo S, Demetris A, Ueda Y et al. Renal transplantation in baboons under FK 506. Surgery 1989; 106: 444–451

11. Abbas AK, Lichtman AH, Pober JS (eds). Cellular and Molecular Immunology. 4th edn. Philadelphia: WB Saunders Company, 2000

12. Sompayrac L. How the Immune System Works. Oxford: Blackwell Science, 1999

13. Tocci MJ, Matkovich DA, Collier KA et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989; 143: 718–726

14. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506.Immunol Today 1992; 13: 136–142

15. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes

16. Schreiber SL, Liu J, Albers MW et al. Immunophilin-ligand complexes as probes of intracellular signaling pathways. Transplant Proc 1991; 23: 2839–2844

17. Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993; 14: 290–295

18. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK 506 and cyclosporin A. Nature 1991; 352: 803–807

19. Adams DH, Liu Q. FK506 inhibits human lymphocyte migration and the production of lymphocyte chemotactic factors in liver allograft recipients. Hepatology 1996; 23: 1476–1483

20. Wada T, Tomosugi N, Kobayashi K et al. Appearance of interleukin-8 in the urine predicts acute rejection of renal transplantation (letter). Nephrol Dial Transplant 1994;9:874–875

21. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17: 584–591

22. Plosker GL, Foster RH. Tacrolimus. A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 323–389

23. Migita K, Eguchi K, Kawabe Y et al. FK506 augments activation-induced programmed cell death of T lymphocytes in vivo. J Clin Invest 1995; 96: 727–732

24. Migita K, Eguchi K, Kawabe Y et al. FK506 potentiates steroid induced T cell apoptosis. Transplantation 1997; 64: 1365–1369

25. Migita K, Eguchi K. FK 506-mediated T-cell apoptosis induction. Transplant Proc 2001; 33: 2292–2293

26. Margreiter R for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359:741–746

27. Del Castillo D, for the European Tacrolimus vs Cyclosporin-Microemulsion (CyA-ME) Renal Transplantation Study Group. Analysis of primary and recurrent rejection following renal transplantation in a large, comparative, multicentre trial. Transplant Proc 2001; 33: 1259–1261

28. Reed EF, Hong B, Ho E et al. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant associated coronary artery disease. Transplantation 1996; 61: 566–572

29. Dunn MJ, Crisp S, Rose ML et al. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 1992; 339: 1566–1570

30. Wheeler C, Collins A, Dunn MJ et al. Identification of anti-endothelial cell antibodies associated with accelerated coronary artery disease after cardiac transplantation. J Heart Lung Transplant 1994; 14: 188–197

31. Kobashigawa JA, Takemoto S, Wener L et al. Development of circulating IgG class I antibodies is associated with increase in intimal thickness by intravascular ultrasound (IVUS) after heart transplant. J Heart Lung Transplant 2000; 19: 81–82 (Abstract 186)

32. Jurcevic S, Dunn MJ, Crisp S et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. Transplantation 1998; 65: 1197–1202

33. Kobashigawa JA, Moriguchi JD, Takemoto S et al. First year results of a randomized trial of tacrolimus vs Neoral cyclosporine in heart transplant patients. J Heart Lung Transplant 2000; 19: 47 (Abstract 37)

34. Mayer AD for the European Tacrolimus Multicentre Renal Study Group. Chronic rejection and graft half-life: five-year follow-up of the European tacrolimus multicenter renal study. Transplant Proc 2002; 34: 1491–1492

35. Jinquan T, Larsen CG, Gesser B et al. Human-IL-10 is a chemoattractant for CD8+ T-lymphocytes and inhibitor of IL-8 induced CD4+ lymphocyte migration. J Immunol 1993;151:4545–4551

36. Hutchinson IV, Bagnall W, Bryce P et al. Differences in the mode of action of cyclosporine and FK 506. Transplant Proc 1998; 30: 959–960

37. Brogan IJ, Geraghty PJ, Hutchinson IV. Interaction of immunophilin-binding immunosuppressives with the glucocorticoid receptor signaling pathway: implications for transplantation. Transplant Proc 2001; 33: 2417–2419

38. Chen ZK, Cobbold SP, Waldmann H, Metcalfe S. Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation 1996; 62: 1200–1206

39. Grace SS, Barradas MA, Mikhailidis DP et al. Cyclosporine A enhances platelet aggregation. Kidney Int 1987; 32: 889–895

40. Muraki T, Sasaki Y, Gidding JC et al. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. Transplantation 1995; 60: 308–310

41. Freudenberger R, Alexis J, Gass A et al. Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy. J Heart Lung Transplant 1999; 18: 1228–1231

42. Hutchinson IV. The role of transforming growth factor beta in transplant rejection. Transplant Proc 1999; 31[Suppl.7A]: 9S–13S

43. Branton MH, Kopp JB. TGF-βand fibrosis. Microbes Infect 1999; 1: 1349–1365

44. McCaffrey TA. TGF-βs and TGF-βreceptors in atherosclerosis. Cytokine Growth Factor Rev 2000; 11: 103–114

45. Shin GT, Khanna A, Ding R et al. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation 1998;65:313–318

46. Mohamed MA, Robertson H, Booth TA et al. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. Transplantation 2000; 69: 1002–1005

47. El-Gamel A, Awad M, Yonan M et al. Does cyclosporin promote the secretion of transforming growth factor-beta1 following pulmonary transplantation? Transplant Proc 1998; 30:1525–1527

48. Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of the TGF-βfamily with the immunophilin FKBP-12. Science 1994; 265: 674–676

49. Baan CC, van Riemsdijk IC, Balk AHMM et al. Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-β1 type I receptor expression. Clin Transplant 2001; 15: 276–283

50. Coupes BM, Williams S, Roberts ISD et al. Differential expression of TGF-βduring immunosuppression with tacrolimus and cyclosporin (CsA) in human renal allograft recipients. J Am Soc Nephrol 1999; 10: 725A (Abstract A3668)

51. Baboolal K, Jones GV, Janezic AL et al. Molecular and structural consequences of early renal allograft injury. Kidney Int 2002; 61: 686–696

52. Jette L, Beaulieu E, Leclerc JM, Beliveau R. Cyclosporin A treatment induces overexpression of p-glycoprotein in the kidney and other tissues. Am J Physiol 1996; 270: F756–65

53. Hauser IA, Koziolek M, Hopfer U, Thevenod F. Therapeutic concentrations of cyclosporine A, but not FK506, increase p-glycoprotein expression in endothelial and renal tubule cells. Kidney Int 1998; 54: 1139–1149

54. Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999; 39: 995–1005

55. Zanker B, Barth C, Stachowski J et al. Multidrug resistance gene MDR1 expression: a gene transfection in vitro model and clinical analysis in cyclosporine-treated patients rejecting their renal grafts. Transplant Proc 1997; 29: 1507–1508

56. Kino T, Hatanaka H, Hashimoto M et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 1987; 40: 1249–1255

57. Tanaka H, Kuroda A, Marusawa H et al. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc1987;19 [Suppl.6]:11–16

58. Honbo T, Kobayashi M, Hane K et al. The oral dosage form of FK-506. Transplant Proc 1987; 19[Suppl.6]: 17–22

59. Venkataramanan R, Jain A, Warty VS et al. Pharmacokinetics of FK506 in transplant patients. Transplant Proc 1991; 23: 2736–2740

60. Undre NA, van Hooff J, Christiaans M et al. Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. Transplant Proc 1998; 30: 1299–1302

61. Webb NJA, Stevenson PJ, Lewis MA et al. Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. Transplant Proc 2002; 34: 1948–1950

62. Moller A, Iwasaki K, Kawamura A et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 1999; 27: 633–636

63. Mekki Q, Lee C, Aweeka F et al. Pharmacokinetics of tacrolimus (FK506) in kidney transplant patients. Clin Pharmacol Ther 1993; 53: 238 (Abstract PIII-130)

64. Mekki Q, Lee C, Carrier S et al. The effect of food on oral bioavailability of tacrolimus (FK506) in liver transplant patients. Clin Pharmacol Ther 1993;53:229 (Abstract PIII-92)

65. Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5mg single oral doses to healthy human subjects. Clin Pharmacol 2001; 41: 176–182

66. Duijnhoven EM, Christiaans MH, Boots JM, van Hooff JP. Evidence that fasting does not significantly affect trough levels of tacrolimus in stable renal transplant recipients. Transplant Proc 2002 Aug;34(5):1723-1725

67. Christiaans M, van Duijnhoven E, Beysens T et al. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc 1998 Jun; 30(4): 1271-1273

68. Venkataramanan R, Jain A, Cadoff E et al. Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc 1990; 22 [Suppl. 1]: 52–56

69. Beysens AJ, Wijnen RMH, Beuman GH et al. FK506: monitoring in plasma or whole blood? Transplant Proc 1991; 23: 2745–2747

70. Machida M, Takahara S, Ishibashi M et al. Effect of temperature and hematocrit on plasma concentration of FK 506. Transplant Proc 1991; 23:2753–2754

71. Kolars C, Merion R, Awni WM, Watkins PB. First pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488–1490

72. Lampen A, Christians U, Guengerich FP et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos1995;23 : pp. 1315–1324

73. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem YF. Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients Source.Kidney International 2004; 66(1): 433-440

74. Karanam BV, Vincent SH, Lee Chiu SH. Drug Metab Dispos 1994; 811

75. Iwasaki K, Shiraga T, Nagase K et al. Isolation, identification and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos 1993; 21: 971–977

76. Iwasaki K, Shiraga T, Matsuda H et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 1995; 23: 28–34

77. Zhao Y, Song M, Guan D et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplantation Proceedings 2005; 37(1): 178-181

78. Manzanares C. Therapeutic drug monitoring of tacrolimus: a moving matter. Therapie 2002; 57(2): 133-136

79. Lee C, Jusko W, Schaefer M et al. Pharmacokinetics of tacrolimus (FK506) in liver transplant patients. Clin Pharmacol Ther 1993;53:181 (Abstract PI-46)

80. Undre NA, Schafer A, and the European Tacrolimus Multicentre Renal Study Group. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. Transplant Proc 1998; 30: 1261–1263

81. Jain AB, Fung JJ, Tzakis AG et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplant Proc 1991; 23: 2763–2766

82. Sewing K-Fr. Pharmacokinetics, dosing principles and blood level monitoring of FK506. Transplant Proc 1994; 26: 3267–3269

83. Mathis AS, Shah N, Friedman GS et al. Pharmacokinetic interaction of chloramphenicol with calcineurin inhibitors. Am J Transplant 2001; 1[Suppl.1]: 140 (Abstract 18)

84. Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant 2001; 15: 95–99

85. Manez R, Martin M, Venkataramanan R et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994; 57: 1521–1523

86. Wolter K,Wagner K, Philipp T, Fritschka E. Interaction between FK 506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol 1994; 47: 207–208

87. McCauley J, Fung J, Jain A, Todo S, Starzl TE. The effects of FK 506 on renal function after liver transplantation. Transplant Proc 1990; 22[Suppl.1]: 17–20

88. Shapiro R, Venkataramanan R, Warty VS et al. FK 506 interaction with danazol. Lancet 1993; 341: 1344–1345

89. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999; 33: 680–682

90. Furlan V, Perello L, Jacquemin E et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation 1995; 59: 1217–1218

91. Vincent I, Furlan V, Debray D et al. Effects of antifungal agents on the pharmacokinetics and nephrotoxicity of FK 506 in paediatric liver transplant recipients. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, USA, 1995

92. Thompson PA, Mosley CA. Tacrolimus-phenytoin interaction. Ann Pharmacother 1996; 30: 544

93. Bolley R, Zuelke C, Kammerl M et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John’s wort. Transplantation 2002; 73: 1009

94. Breidenbach T, Kliem V, Burg M et al. Profound drop of cyclosporin A whole blood trough levels caused by St. Johnґs wort (Hypericum perforatum). Transplantation 2000; 69: 2229-2230

95. Hariharan S, Tomlanovich SJ, Filo RS et al. Pharmacokinetics (PK) and tolerability of tacrolimus and sirolimus combination therapy in stable renal transplant recipients. Am J Transplant 2001; 1[Suppl. 1]:406 (Abstract 1074)

96. Duijnhoven EM, Boots JM, Christiaans MH et al. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003; 16(10): 721-725

97. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: Consequences for FK 506 assimilation. Kidney international 2005; 67(3): 1152-1160

98. Iwasaki K, Miyazaki Y, Teramura Y et al. Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid. Res Commun Mol Pathol Pharmacol 1996; 94: 251–257

99. Undre NA. Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 2003; 18[Suppl.1]: 12-15

100. Undre NA, van Hooff J, Christiaans M et al. Pharmacokinetics (PK) of tacrolimus (TAC) and rapamycin (RAPA) following the administration of different doses of RAPA in combination with TAC in kidney transplantation. 2nd International Congress on Immunosuppression, San Diego, California, USA, 2001. Abstract P-66

101. Schubert M, Venkataramanan R, Holt DW et al. Pharmacokinetics of sirolimus and tacrolimus in pedriatric transplant patients. Am J Transplant 2004; 4: 767-773

102. Schachter AD, Benfield MR, Wyatt RJ et al. Sirolimus pharmacokinetics in pedriatric renal transplant recipients rceiving calcineurin inhibitor co-therapy. Pediatr Transplant 2006; 10: 914-919

103. Kovarik JM, Kalbag J, Figueiredo J et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002; 42: 95

104. Kovarik JM, Curtis JJ, Hricik DE et al. Everolimus and calcineurin inhibitors: different pharmacokinetic drug interaction with tacrolimus vs cyclosporine in kidney transplant patients. Transplantation 2006; 82 (1)[Suppl 2]: 867

105. Kovarik JM, Curtis JJ, Hricik DE et al. Differential pharmacokinetic interaction of tacolimus and cyclosporine on everolimus. Transplant Proc 2006; 38: 3456-3458

106. Chan L, Cibrik D, Munir L, Shaw LM. for the CRAD001AUS Study group. No Pharmacokinetic Interaction Evident In De Novo Kidney Transplant Recipients Treated With Everolimus, basiliximab and Reduced Tacrolimus Exposure For 6 Months. WTC2006—The World Transplant Congress, 22-27 July 2006, Boston, USA – Web Site (2006), p. 487, Abstr. 1246

107. Shaw LM, Holt DW, Keown P et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther 1999; 21: 1632–1652

108. Undre N, van Hooff J, Christiaans M et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31: 296–298

109. Undre N, Stevenson P, Schafer A. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc 1999; 31[Suppl.7A]: 21S–24S

110. Uhlmann D, Pridoehl O, Rhein T et al. Conversion to low-dose tacrolimus / sirolimus or sirolimus monotherapy after liver transplantation and calcineurin inhibitor induced nephroxicity results in stabilization or improvement of kidney function – a prospective study. American Journal of Transplantation 2005; 5[Suppl. 11]: 472, Abstr. 1238

111. Kuypers D, Evenepoel P, Maes B et al. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clinical Transplantation 2003; 17(3): 234-241

112. El-Dahshan KF, Bakr MA, Donia AF et al. Co-administration of ketoconazole to tacrolimus-treated kidney transplant recipients: a prospective randomized study. Nephrol Dial Transplant 2004; 19: 1613–1617

113. Taylor PJ, Jones A, Balderson GA et al. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 1996;42:279–285

114. Tredger JM. Tacrolimus monitoring. Syva Drug Monitor. The Journal of Dade Behring Ltd 2000; 3: 60–62

115. Grenier FC, J Bergmann LM, S Morrison LM et al. A whole blood FK506 assay for the IMx analyzer. Transplant Proc 1991; 23: 2748–2749

116. Cogill JL, Taylor PJ, Westley IS et al. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem1998; 44: 1942–1946

117. Braun F, Schutz E, Christians U et al. Pitfalls in monitoring tacrolimus (FK506). Ther Drug Monit 1997;19: 628–631

118. Jusko WJ, Thomson AW, Fung J et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995; 17: 606

119. Staatz CE, Taylor PJ, Tett SE. Comparison of an ELISA and an lc/Ms/Ms method for measuring tacrolimus concentrations and making dosage decisions in transplant recipients. Therapeutic Drug Monitoring 2002; 24(5): 607-615

120. Cannon RD, Wong SHY, Harihan S et al. Clinical efficacy of the Abbott Tacrolimus II assay for the IMx. Ann Clin Lab Sci 1999; 4: 299–302

121. Salm P, Rutherford DM, Taylor PJ et al. Evaluation of microparticle enzyme immunoassay against HPLC-mass spectrometry for the determination of whole-blood Tacrolimus in heart-and lung-transplant recipients. Clin Biochem 2000; 33: 557–562

122. Poquette MA, Lensmeyer GL, Doran TC.Effective use of liquid chromatography-mass spectrometry (LC/MS) in the routine clinical laboratory for monitoring sirolimus, tacrolimus, and cyclosporine. Therapeutic drug monitoring 2005; 27(2): 144-150

123. Chusney GD, Borrows RJ, Cairns TDH et al. Liquid Chromatography with Tandem Mass Spectrometry: A Precise and Specific Method for Routine Therapeutic Monitoring of Tacrolimus. 7th Annual Congress of The British Transplantation Society, 28 – 30 April 2004, The International Convention Centre, Birmingham, UK (2004), p. 89, Abstr. 036

124. Borrows R, Chusney G, Loucaidou M et al. Tacrolimus Monitoring in Renal Transplantation: A Comparison Between High-Performance Liquid Chromatography and Immunoassay. Transplantation Proceedings 2005; 37(4): 1733-1735

125. Borrows R, Chusney G, Loucaidou M et al. Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus. Therapeutic Drug Monitoring 2006; 28(2): 269-273

126. Jusko WJ, Piekoszewski W, Klintmalm GB et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther1995; 57: 281-290

127. Pereira LM, de Castro MCR, Ventura CG et al. C2 A single-point strategy for monitoring of tacrolimus, mycophenolic acid and cyclosporine in kidney transplantation. WTC2006—The World Transplant Congress, 22-27 July 2006, Boston, USA – Web Site (2006), p. 346, Abstr. 827

128. Uchida K, Tominaga Y, Haba T et al. Investigation of the optimal monitoring of mycophenolate mofetil and tacrolimus in renal transplant immunosuppressive therapy: is there really no problem with trough monitoring? American J Transplant 2004; 4[Suppl. 8]: 237, Abstr. 287

129. Pereira L, Castro M, Mattos R et al. C2 monitoring for tacrolimus, MPA and CYA. A single approach for therapeutic drug monitoring. Transplantation 2004; 78 [Suppl.2]: 279, Abstr. P244

130. Mayer AD. Dmitrewski J, Squifflet J-P et al. Multicenter randomized trial comparing tacrolimus (FK-506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997; 64: 436-443

131. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS for the FK-506 Kidney Transplant Study Group: A comparison of tacrolimus (FK-506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-983

132. Fung JJ, Alessiani M, Abu-Emagd K et al. Adverse effects associated with the use of FK-506. Transplant Proc 1991; 23: 3105-3108

133. Yamada K, Sugisaki Y, Akimoto M, Yamanaka N. FK-506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney – morphologic and biologic analysis. Transplant Proc 1992; 24: 1396-1398

134. Moutabarrik A, Ishibashi M, Fukunaga M et al. FK-506-induced kidney tubular cell injury. Transplantation 1992; 54: 1041-1047

135. Randhawa PS, Shapiro R, Jordan ML et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Am J Surg Pathol 1993; 17: 60–68

136. Bennett WM, Burdmann EA, Andoh TF et al. Nephrotoxicity of immunosuppressive drugs. Nephrol Dial Transplant 1994; 9[Suppl.4]: 141–145

137. Martin MF. Editorial: nephrotoxic effects of immunosuppression. Mayo Clin Proc 1994; 69: 191–192

138. McCauley J. The nephrotoxicity of FK-506 as compared with cyclosporine. Nephrol Hypertens 1993; 2: 662-669

139. McCauley J, Takaya S, Fung J et al. The question of FK506 nephrotoxicity after liver transplantation. Transplant Proc 1991; 23: 1444–1447

140. Textor SC, Wiesner R, Wilson DJ et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55: 1332–1339

141. Tarantino A. Rejection and other renal complications. In: Kahan BD, Ponticelli C, editors. Principles and Practice of Renal Transplantation. London: Martin Dunitz Ltd, 2000. p. 481–524

142. Devlin J, Williams R, Neuhaus P et al. Renal complications and development of hypertension in the European study of FK-506 and cyclosponn in primary liver transplant recipients. Transplant Int 1994; [Suppl7]: 22-26

143. Mayer AD for the European Tacrolimus Multicentre Renal Study Group. Four-year follow-up of the European tacrolimus multicentre renal study. Transplant Proc 1999; 31[Suppl. 7A]: 27S–28S

144. Vincenti F, Jensik SC, Filo RS et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775–782

145. Montagnino G, Kramer BK, Arias M for the European Tacrolimus vs. Cyclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: twelve-month follow-up.Transplant Proc 2002; 34: 1635–1637

146. Ruiz San Millan JC, Arias M, Kraemer BK, Montagnino G for The European Tacrolimus vs Ciclosporin Renal Transplantation Study Group. Tacrolimus versus ciclosporin microemulsion in renal transplantation: the two year follow-up results. Transplantation 2002; 74: 59 (Abstract 138)

147. Filler G, Trompeter R, Webb NJA et al. One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomised trial of tacrolimus vs cyclosporine microemulsion. Transplant Proc 2002; 34: 1935–1938

148. Jurewicz WA. Tacrolimus versus Ciclosporin immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003; 18[Suppl.1]: 7-11

149. Squifflet J-P, Backman L, Claesson K et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2002; 72: 63–69

150. Miller J, Mendez R, Pirsch JD, Jensik SC, for the FK506/MMF Dose-ranging Kidney Transplant Study Group. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Transplantation 2000; 69: 875–880

151. Wlodarczyk Z, van Hooff JP, Vanrenterghem Y et al. Tacrolimus in combination with various dosages of rapamycin in renal recipients: safety and efficacy of the first 6-month multicenter randomised trial. Transplantation 2002; 74[Suppl.]:187 (Abstract 554)

152. Kliem V, Schaumann D, Ehlerding G et al. Long-term results after primary successful FK-506 treatment of steroid or OKT3-resistant rejection in renal transplant recipients. Transplant Proc 1997; 29: 2955-2957

153. Kliem V, Radermacher J, Hiss M et al. Conversion to tacrolimus for acute corticosteroid-and antibody-resistant rejection following kidney transplantation. Transplant Proc 1999; 31: 37S-40S

154. Platz KP, Muller AR, Blumhardt G et al. Nephrotoxicity following orthotopic liver transplantation. Transplantation 1994; 58: 170-178

155. Singh N, Gayowski T, Marino IR. Hemolytic uremic syndrome in solid-organ transplant recipients. Transplant Int 1996;9:68-75

156. Schmidt RJ, Venkat KK, Dumler F: Hemolytic-uremic syndrome in a renal transplant recipient on FK-506 immunosuppression. Transplant Proc 1991;23:3156-3157

157. Kaufman DB, Kaplan B, Kanwar YS et al. The successful use of tacrolimus (FK-506) in a pancreas/kidney transplant recipient with recurrent cyciosporine-associated hemolytic uremic syndrome. Transplantation 1995;59:1737-1739

158. Abdalla AH, Al-Sulaiman MH, Al-Khader AA. FK-506 as an alternative in cyclosporin-induced hemolytic uremic syndrome in a kidney transplant recipient. Transplant Int 1994;7:382-384

159. Starzl TE. Experience in renal transplantation. Philadelphia: Saunders, 1964, p. 117

160. Boudreaux JP, McHugh L, Canafax DM et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987;44:376–381

161. Roth D, Milgrom M, Esquenazi V et al. Posttransplant hyperglycemia. Increased incidence in cyclosporine-treated renal allograft recipients. Transplantation 1989;47:278–281

162. Krentz AJ, Dmitrewski J, Mayer D, Nattrass M. Effects of immunosuppressive agents on glucose metabolism. Clin Immunother 1995;4:103–123

163. Jindal RM, Sidner RA, Milgrom ML. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 1997;16: 242–257

164. Mihatsch MJ, Kyo M, Morozumi K et al. The side effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998;49: 356–363

165. Drachenberg CB, Klassen DK, Weir MR et al. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999;68: 396–402

166. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: Meta-analysis of randomised trials. BMJ 1999;318(7191): 1104–1107

167. Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999;34:1–13

168. World Health Organization. Diabetes Mellitus. Report of a WHO Study Group. World Health Organization Technical Report Series 727, Geneva, 1985

169. Cavaille-Coll MW, Elashoff MR. Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1998;65:142–145

170. Duijnhoven EM, Boots JMM, Christiaans MHL et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrology 2001;12: 583–588

171. Nam JH, Mun JI, Kim SI et al. b-cell dysfunction rather than insulin resistance is the main contributing factor for development of postrenal transplantation diabetes mellitus. Transplantation 2001;71:1417–1423

172. Schwimmer J, Zand MS. Management of diabetes mellitus after solid organ transplantation. Graft 2001;4:256–65

173. Trompeter R, Filler G, Webb NJA et al. Randomized trial of tacrolimus versus cyclosporine microemulsion in renal transplantation. Pediatr Nephrol 2002;17:141–149

174. Kramer B, Montagnino G, Castillo D et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005;20:968–973

175. Hooff JP, Christiaans MHL, van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant 2004;19[Suppl. 6]: vi8-vi12

176. Jindal RM, Salmela K, Vanrenterghem Y et al. European Tacrolimus/MMF Transplantation Study Group. Reduction of high cholesterol levels by early withdrawal of steroids from a tacrolimus-based triple regimen. Am J Transplant 2002;2[Suppl. 3]:190 (Abstract 206)

177. Pascual J, van Hooff JP, Salmela K et al. Long-term efficacy and safety of steroid withdrawal in tacrolimus-treated renal transplant recipients: results of a 3-year follow-up. Am J Transplant 2004; 4[Suppl. 8]: 576-577, Abstr. 1524

178. Rostaing L et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807-814

179. Shapiro R, Jordan M, Scantlebury V et al. FK-506 in clinical kidney transplantation. Transplant Proc 1991;23:3056-3067

180. Schleibner S, Krauss M, Wagner K et al. FK-506 versus cyclosporin in the prevention of renal allograft rejection – European pilot study: six-week results. Transplant Int 1995;8:86-90

181. Laskow DA and FK506 Kidney Transplant Study Group. Hypertension in renal transplant recipients: 2-year results from the FK506 multicenter, randomized comparative trial. The International Congress on Immunosuppression, Orlando, Florida, USA, 1997. Abstract 77

182. Radermacher J, Meiners M, Bramlage C et al. Pronounced renal vasoconstriction and systemic hypertension by cyclosporine compared to FK-506 in renal transplant patients. Transplant Int 1998;11:3-10

183. Benigni A, Mongi M, Penco N et al. The acute affect of FK-506 and cyclosporine on endothelial function and renal vascular resistance. Transplantation 1992;54: 775-780

184. Jensik SC and the FK 506 Kidney Transplant Study Group. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc 1998;30:1216–1218

185. Claesson K, Mayer AD, Squifflet J-P et al. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. Transplant Proc 1998;30:1292–1294

186. Kramer BK, Zulke C, Kammerl MC et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. European Tacrolimus vs. Cyclosporine Microemulsion Renal Transplantation Study Group. Am J Transplant 2003; 3(8):982-987

187. Squifflet J-P, Vanrenterghem Y, van Hooff JP et al. and the European Tacrolimus/MMF Transplantation Study Group. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicentre, randomised study. Transplant Proc 2002;34:1584–1586

188. Margreiter R, Pohanka E, Sparacino V et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects. Transplant International 2005; 18(7): 816-823

189. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69:834–841

190. Charpentier B for the European Tacrolimus vs Microemulsified Cyclosporin Study Group. A three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in ad renal transplant recipients. Transplant Proc 2002;34:1625–1626

191. Burke GW, Ciancio C, Blomberg BB et al. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection. Transplantation Proceedings 2002; 34(5): 1610-1611

192. Atkison P, Joubert G, Barren A et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995; 345:894-896

193. Williams R, Neuhaus P, Bismuth H et al. Two-year data from the European multicentre tacrolimus (FK506) liver study. Transpl Int 1996;9[Suppl.1]:10/1–7

194. Mor E, Sheiner PA, Schwartz ME et al. Reversal of severe FK 506 side effects by conversion to cyclosporine-based immunosuppression. Transplantation 1994;58: 380-382

195. Hytirogiu P, Lee R, Sharma K et al. FK-506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Transplantation 1993;56:1389-1394

196. Fisher A, Mor E, Hytiroglou P et al. FK-506 hepatotoxicity in liver allograft recipients. Transplantation 1995;59:1631-1632

197. Lufft V, Kliem V, Behrend M et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Transplantation 1996;62:421-423

198. Eberhard OK, Kliem V, Oldhafer K et al. How best to use tacrolimus (FK-506) for treatment of steroid-and OKT3-resistant rejection after renal transplantation. Transplantation 1996;61:1345-1349

199. Jordan ML, Shapiro R, Jensen CWB et al. FK-506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc 1991;23:3078-3081

200. Yang H, Gonwa T, Rice K et al. Sirolimus vs mycophenolate mofetil – results of the first US multicenter kidney transplant study with tacrolimus combination therapy. Transplantation 2002;74[Suppl.]:188 (Abstract 557)

201. Pascual J, Vanrenterghem Y, van Hooff J et al. Safe withdrawal of MMF or steroids following 3 months of tacrolimus triple therapy: results of a large, prospective, multicentre study. Transplantation 2002;74:427 (Abstract 2105)

202. Pappo O, Demetris AJ, Raikow RB, Randhawa PS. Human polyoma virus infection of renal allografts: histopathologic diagnosis, clinical significance, and literature review. Mod Pathol 1996;9:105-109

203. Randhawa PS, Finkelstein S, Scantlebury V et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999;67:103-109

204. Howell DN, Smith SR, Butterly DW et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999;68:1279-1288

205. Drachenberg CB, Beskow CO, Cangro CB et al. Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. Hum Pathol 1999;30:970-977

206. Binet I, Nickeleit V, Hirsch HH et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 1999;67:918-922

207. Nickeleit V, Klimkait T, Binet IF et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000;342:1309-1315

208. Mathur VS, Olson JL, Darragh TM, Yen TSB. Polyomavirus-induced interstitial nephritis in two renal transplant recipients: case reports and review of the literature. Am J Kidney Diseases 1997;29(5): 754-758

209. Kim HC, Hwang EA, Kang MJ et al. BK virus infection in kidney transplant recipients. Transplant Proceedings 2004;36(7): 2113-2115

210. Brennan DC, Agha I, Bohl DL et al. Incidence of BK with Tacrolimus Versus Cyclosporine and Impact of Preemptive Immunosuppression Reduction.Am J Transplant 2005;5(3): 582-594

211. Ramos E, Drachenberg CB, Papadimitriou JC et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Amer Society Nephrology 2002;13(8): 2145-2151

212. Cox LK, Lawrence-Miyasaki LS, Garcia-Kennedy R et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK-506 after liver transplantation. Transplantation 1995:59:524-529

213. Shapiro R, Scantlebury VP, Jordan ML et al. FK506 in pediatric kidney transplantation – primary and rescue experience. Pediatr Nephrol 1995;9:43–48

214. Shapiro R, Scantlebury VP, Jordan ML et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999;67:299–303

215. Shapiro R, Nalesnik M, McCauley J et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999;68:1851–1854